Last reviewed · How we verify
BYOOVIZ (RANIBIZUMAB-NUNA)
BYOOVIZ (generic name: RANIBIZUMAB-NUNA) is a drug developed by SAMSUNG BIOEPIS CO LTD. It is currently FDA-approved for Age related macular degeneration, Branch retinal vein occlusion with macular edema, Central retinal vein occlusion with macular edema.
BYOOVIZ is a vascular endothelial growth factor A inhibitor, classified as an antibody drug. It targets vascular endothelial growth factor A, long form, and is used to inhibit its activity.
At a glance
| Generic name | RANIBIZUMAB-NUNA |
|---|---|
| Sponsor | SAMSUNG BIOEPIS CO LTD |
| Target | Vascular endothelial growth factor A |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Age related macular degeneration
- Branch retinal vein occlusion with macular edema
- Central retinal vein occlusion with macular edema
- Choroidal retinal neovascularization
- Diabetic retinopathy
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Retinopathy of prematurity
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Vitreous floaters
- Intraocular pressure increased
- Vitreous detachment
- Intraocular inflammation
- Cataract
- Foreign body sensation in eyes
- Eye irritation
- Lacrimation increased
Serious adverse events
- Endophthalmitis
- Rhegmatogenous retinal detachment
- Iatrogenic traumatic cataract
- Tear of retinal pigment epithelium
- Thromboembolic events
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BYOOVIZ CI brief — competitive landscape report
- BYOOVIZ updates RSS · CI watch RSS
- SAMSUNG BIOEPIS CO LTD portfolio CI
Frequently asked questions about BYOOVIZ
What is BYOOVIZ?
What is BYOOVIZ used for?
Who makes BYOOVIZ?
What is the generic name of BYOOVIZ?
What development phase is BYOOVIZ in?
What are the side effects of BYOOVIZ?
What does BYOOVIZ target?
Related
- Target: All drugs targeting Vascular endothelial growth factor A
- Manufacturer: SAMSUNG BIOEPIS CO LTD — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Age related macular degeneration
- Indication: Drugs for Branch retinal vein occlusion with macular edema
- Indication: Drugs for Central retinal vein occlusion with macular edema
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing